Stockreport

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Rallybio Corporation  (RLYB) 
PDF – Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement- [Read more]